TABLE 1.

Number and percentage of facilities reporting carbapenem-resistant^* Enterobacteriaceae^† from a catheter-associated urinary tract infection (CAUTI) or a central-line–associated bloodstream infection (CLABSI), by selected characteristics — United States, National Healthcare Safety Network, January–June 2012

Characteristic	No. of facilities with carbapenem-resistant Enterobacteriaceae from CAUTI or CLABSI	Total no. of facilities performing CAUTI or CLABSI surveillance (N = 3,918)	(%)§¶
Facility type
All acute-care hospitals	181	3,918	(4.6)
Short-stay acute-care hospital	145	3,716	(3.9)
Long-term acute-care hospital	36	202	(17.8)
Hospital size (no. of beds)
<100	48	1,609	(3.0)
100–299	46	1,480	(3.1)
300–499	41	541	(7.6)
≥500	45	258	(17.4)
Medical school affiliation
Yes	102	1,079	(9.5)
No	53	2,839	(1.9)
U.S. Census region **
Northeast	63	658	(9.6)
Midwest	30	927	(3.2)
South	50	1,503	(3.3)
West	29	804	(3.6)
Other††	9	26	(34.6)

^*Intermediate or resistant to imipenem, meropenem, or doripenem.

^†Klebsiella pneumoniae, Klebsiella oxytoca, Escherichia coli, Enterobacter aerogenes, or Enterobacter cloacae.

^§Total percentage of facilities performing any surveillance for any CAUTI and CLABSI during the first 6 months of 2012.

^¶For each category, p<0.01 by chi-square test.

^**Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont; Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin; South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West Virginia; West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming.

^††Armed Forces, Puerto Rico, and U.S. Virgin Islands.